ALTERED CD20 CONFORMATION AT THE CELL SURFACE OF RITUXIMAB REFRACTORY TUMOR CELLS - A NOVEL MECHANISM OF RITUXIMAB RESISTANCE

被引：0
|
作者：
Shimada, K. [1 ]
Tomita, A. [2 ]
Tokunaga, T. [2 ]
Iriyama, C. [2 ]
Kinoshita, T. [2 ]
Glennie, M. [1 ]
Johnson, P. [1 ]
Naoe, T. [2 ]
机构：
[1] Univ Southampton, Sch Med, Gen Hosp, Canc Sci Div, Southampton, Hants, England
[2] Nagoya Univ, Dept Hematol & Oncol, Grad Sch Med, Nagoya, Aichi 4648601, Japan
来源：
ANNALS OF ONCOLOGY | 2011年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：241 / 241
页数：1
相关论文
共 50 条
  • [31] Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas
    Schuster, Stephen J.
    Huw, Ling-Yuh
    Bolen, Christopher R.
    Maximov, Victor
    Polson, Andrew G.
    Hatzi, Katerina
    Lasater, Elisabeth A.
    Assouline, Sarit E.
    Bartlett, Nancy L.
    Budde, L. Elizabeth
    Matasar, Matthew J.
    Koeppen, Hartmut
    Piccione, Emily C.
    Wilson, Deanna
    Wei, Michael C.
    Yin, Shen
    Penuel, Elicia
    [J]. BLOOD, 2024, 143 (09) : 822 - 832
  • [32] Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia
    Aue, Georg
    Lindorfer, Margaret A.
    Beum, Paul V.
    Pawluczkowycz, Andrew W.
    Vire, Berengere
    Hughes, Thomas
    Taylor, Ronald P.
    Wiestner, Adrian
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (02): : 329 - 332
  • [33] Establishment of a novel CD20 negative mature B-cell line, WILL2, from a CD20 positive diffuse large B-cell lymphoma patient treated with rituximab
    Takashi Sonoki
    Yaqiong Li
    Setsuko Miyanishi
    Hirokazu Nakamine
    Nobuyoshi Hanaoka
    Hiroshi Matsuoka
    Ichiro Mori
    Hideki Nakakuma
    [J]. International Journal of Hematology, 2009, 89 : 400 - 402
  • [34] Establishment of a novel CD20 negative mature B-cell line, WILL2, from a CD20 positive diffuse large B-cell lymphoma patient treated with rituximab
    Sonoki, Takashi
    Li, Yaqiong
    Miyanishi, Setsuko
    Nakamine, Hirokazu
    Hanaoka, Nobuyoshi
    Matsuoka, Hiroshi
    Mori, Ichiro
    Nakakuma, Hideki
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2009, 89 (03) : 400 - 402
  • [35] Superior Efficacy of the Novel Type II, Glycoengineered CD20 Antibody GA101vs. the Type I CD20 Antibodies Rituximab and Ofatumumab
    Herter, Sylvia
    Waldhauer, Inja
    Otz, Tina
    Herting, Frank
    Lang, Sabine
    Nicolini, Valeria
    Roemmele, Michaela
    Friess, Thomas
    Van Puijenbroek, Erwin
    Bacac, Marina
    Weidner, K. Michael
    Gerdes, Christian
    Umana, Pablo
    Klein, Christian
    [J]. BLOOD, 2010, 116 (21) : 1601 - 1601
  • [36] Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab
    Serra-Peinado, Carla
    Grau-Exposito, Judith
    Luque-Ballesteros, Laura
    Astorga-Gamaza, Antonio
    Navarro, Jordi
    Gallego-Rodriguez, Jenny
    Martin, Mario
    Curran, Adria
    Burgos, Joaquin
    Ribera, Esteban
    Raventos, Berta
    Willekens, Rein
    Torrella, Ariadna
    Planas, Bibiana
    Badia, Rosa
    Garcia, Felipe
    Castellvi, Josep
    Genesca, Meritxell
    Falco, Vicenc
    Buzon, Maria J.
    [J]. NATURE COMMUNICATIONS, 2019, 10 (1)
  • [37] CD20-Specific Chimeric Antigen Receptor- Expressing T Cells As Salvage Therapy in Rituximab-Refractory CD20(+) B-Cell Non-Hodgkin Lymphoma
    Li, Xin
    Cheng, Qian
    Liu, Rui
    Kang, Liqing
    Xu, Nan
    Li, Minghao
    Yu, Lei
    [J]. BLOOD, 2021, 138
  • [38] Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab
    Carla Serra-Peinado
    Judith Grau-Expósito
    Laura Luque-Ballesteros
    Antonio Astorga-Gamaza
    Jordi Navarro
    Jenny Gallego-Rodriguez
    Mario Martin
    Adrià Curran
    Joaquin Burgos
    Esteban Ribera
    Berta Raventós
    Rein Willekens
    Ariadna Torrella
    Bibiana Planas
    Rosa Badía
    Felipe Garcia
    Josep Castellví
    Meritxell Genescà
    Vicenç Falcó
    Maria J. Buzon
    [J]. Nature Communications, 10
  • [39] Complement-mediated cytotoxicity of rituximab to CD20 positive myeloma cell line MC/CAR
    Umeda, M
    Kuraishi, Y
    [J]. JOURNAL OF PHARMACOLOGICAL SCIENCES, 2005, 97 : 82P - 82P
  • [40] Influence of cytokines on CD20 expression and Rituximab-induced CDC on MC/CAR myeloma cells
    Umeda, M
    Kuraishi, Y
    Nakai, S
    Furukawa, K
    Akahane, S
    Tsuru, H
    [J]. JOURNAL OF PHARMACOLOGICAL SCIENCES, 2006, 100 : 99P - 99P
12345